Bicycle reports 1 confirmed complete response in BT8009 Phase I; management restructured

BICYCLE THERAPEUTICS PLC

BT8009 Phase I: 4/11 partial responses; one confirmed complete response (100% tumor reduction) at 5.0 mg/m2.
Dose escalation continues at 7.5 mg/m2; interim Phase I results to be presented at a 2022 medical meeting.
BT5528 Phase I/II on track to initiate expansion cohorts in 2022 with RP2D of 6.5 mg/m2 every-other-week.
BT7480 Phase I dose escalation ongoing; four SITC posters on Bicycle TICAs including NK-cell-engaging molecule.
Michael Skynner becomes CTO (new role); Alistair Milnes promoted to COO, both effective Jan 3, 2022.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alistair Milnes

Chief Operating Officer

BCYC · BICYCLE THERAPEUTICS PLC

Effective: 2022-01-03
Filed: January 5, 2022, 6:59 PM ET

On January 5, 2022, Bicycle Therapeutics plc (the “Company”) announced the appointment of Alistair Milnes, age 48, as the Company’s Chief Operating Officer, effective as of January 3, 2022

Role change

Michael Skynner

Chief Technology Officer

BCYC · BICYCLE THERAPEUTICS PLC

Effective: 2022-01-03
Filed: January 5, 2022, 6:59 PM ET

following the transition of Michael Skynner, Ph.D. to the newly-created role of Chief Technology Officer of the Company as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alistair Milnes was appointed as Chief Operating Officer at BICYCLE THERAPEUTICS PLC.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On January 5, 2022, Bicycle Therapeutics plc (the “Company”) announced the appointment of Alistair Milnes, age 48, as the Company’s Chief Operating Officer, effective as of January 3, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Skynner changed role as Chief Technology Officer at BICYCLE THERAPEUTICS PLC.

Action: transitioned to
Role: Chief Technology Officer

Exact text from the filing

following the transition of Michael Skynner, Ph.D. to the newly-created role of Chief Technology Officer of the Company as of the Effective Date.

View on SEC.gov

BICYCLE THERAPEUTICS PLC filing history →

Source: SEC EDGAR

accession 0001104659-22-001252

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.